RDG Share Price | Read-Gene SA Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of 22.5%, the company declared Outstanding results in Dec 25

ROCE(HY) Highest at 32.86%
RAW MATERIAL COST(Y) Fallen by -540.29% (YoY)
DEBT-EQUITY RATIO (HY) Lowest at 0 %

With ROE of 1.55%, it has a expensive valuation with a 0.00 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

2.95

Return on Equity

29.39%

Price to Book

0.00

Revenue and Profits:

Net Sales:

5 Million

(Quarterly Results - Dec 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

-8.33%

1 Year

26.73%

2 Years

2.8%

3 Years

64.18%

4 Years

114.01%

5 Years

61.76%

Read-Gene SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Read-Gene SA Reports Mixed Financial Results Amidst Market Volatility

Read-Gene SA, a micro-cap company in the Pharmaceuticals & Biotechnology sector, has recently released its financial results for the quarter ending June 2025. The performance has been characterized by significant fluctuations, reflecting the challenges faced in the current market environment.

Despite the overall negative financial performance, Read-Gene SA reported some noteworthy metrics. The operating cash flow reached its highest level at PLN 5.11 MM, indicating a strong liquidity position. Additionally, net sales for the half-year period grew by 37.3%, amounting to PLN 6.99 MM, showcasing the company’s ability to increase revenue even amidst adverse conditions.

However, the return on capital employed (ROCE) for the half-year was recorded at -9.22%, highlighting ongoing challenges in effectively utilizing capital. On a positive note, the company experi...

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

18.55%

EBIT Growth (5y)

15.10%

EBIT to Interest (avg)

-0.33

Debt to EBITDA (avg)

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.72

Tax Ratio

4.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.16%

ROE (avg)

1.48%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

7.91

EV to EBITDA

7.91

EV to Capital Employed

0.82

EV to Sales

0.60

PEG Ratio

Dividend Yield

ROCE (Latest)

1.24%

ROE (Latest)

1.55%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 23.81% vs -2.33% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 375.00% vs -500.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.20",
          "val2": "4.20",
          "chgp": "23.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.60",
          "val2": "-0.20",
          "chgp": "900.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.10",
          "val2": "-0.40",
          "chgp": "375.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "281.00%",
          "val2": "-58.90%",
          "chgp": "33.99%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 18.18% vs 30.69% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 172.73% vs 15.38% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.60",
          "val2": "13.20",
          "chgp": "18.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.80",
          "val2": "-1.10",
          "chgp": "172.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "64.40%",
          "val2": "-35.10%",
          "chgp": "9.95%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

5.20

4.20

23.81%

Operating Profit (PBDIT) excl Other Income

1.60

-0.20

900.00%

Interest

0.30

Exceptional Items

0.00

Consolidate Net Profit

1.10

-0.40

375.00%

Operating Profit Margin (Excl OI)

281.00%

-58.90%

33.99%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 23.81% vs -2.33% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 375.00% vs -500.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

15.60

13.20

18.18%

Operating Profit (PBDIT) excl Other Income

1.50

0.00

Interest

0.30

Exceptional Items

0.00

Consolidate Net Profit

0.80

-1.10

172.73%

Operating Profit Margin (Excl OI)

64.40%

-35.10%

9.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 18.18% vs 30.69% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 172.73% vs 15.38% in Dec 2024

All Annual Results

Company CV

About Read-Gene SA

Read-Gene SA

Pharmaceuticals & Biotechnology

Read-Gene SA is a Poland-based company active in the biotechnology sector. It is focused on technologies which aim is to detect, prevent and treat malignant tumors. The Company specializes in three fields: chemoprevention, clinical trials and genetic testing. It offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The Company operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

Company Coordinates

Company Details

Ul. Akacjowa 2 , SZCZECIN None : 71-253

Tel: 48 91 433425648 91 4334256

http://www.read-gene.com/

Registrar Details